ニモディピンの投与量と,亜arachnoid出血の患者の薬理学的な変動性
Judith Bellapart1, María Patricia Hernández-Mitre2, Xiaolin Wu2
1Royal Brisbane and Women's Hospital, Australia.
まとめ
サバラクノイド出血に使用されるニモディピンは,変動する生物学的利用可能性と最小限の脳脊髄液浸透を示しています. 年齢,食物の摂取,投与経路などの要因は,その有効性に影響し,最適化された投与戦略の必要性を示唆しています.
科学分野:
- 薬理学 薬理学とは
- 神経科学は神経科学である.
- クリニック薬局 臨床薬局
背景:
- ニモディピン (Nimodipine) は,動脈節下出血 (SAH) の後の遅発性脳性缺血 (DCI) の唯一の予防策です.
- 現在の定量ニモディピン投与は,DCI治療の有効性に影響を与える患者特有の要因を無視しています.
- ニモディピン薬理学を理解することは,個別化された用量戦略の開発に不可欠です.
研究 の 目的:
- SAH患者における腸内ニモディピンのプラズマおよび脳脊髄液 (CSF) の薬理 Untuak mampunyoi karakteristik farmakokinetika.
- ニモジピン生物学的利用可能性に対する投与経路と栄養状態の影響を調査する.
- ニモディピンの薬理 Untuak manyabuikkan faktor-faktor spesifik dari pasien-pasien nan mangaruhi farmakokinetika nimodipine.
主な方法:
- ニモジピンを投与されたSAH患者の血とCSFのシリアルサンプリング.
- 超高性能液体染色体-タンデム質量スペクトロメトリを用いたニモディピン濃度の定量化.
- 非区画型および非線形混合効果モデリングによる薬物動態分析,経路および給餌状態効果の評価.
主要な成果:
- 2つのコンパートメントの集団の薬理学モデルでは,クリアランスの重要な共変数として年齢を特定しました.
- CSFからプラズマへのニモディピンの平均曝露は0.35%で,CSFへの浸透は最小かつ高度に変動することを示しています.
- 食物摂取はニモディピン生物学的利用性を著しく低下させ,経口および鼻胃経口投与の両方に影響を及ぼしました.
結論:
- ナソガストリック投与および非断食状態ではニモディピン生物利用性が低下する可能性があります.
- ニモディピンは,CSFへの最小かつ変動する浸透を示します.
- 年齢はニモディピンのクリアランスの重要な決定因子であり,最適化された投与と最適な投与量に関するさらなる研究を必要とします.
関連する概念動画
01:24Dosage Regimen: Individualization
216
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
216
01:24Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
286
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
286
01:15Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
402
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
402
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
250
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
250
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
199
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
199
01:29Drug Dosing: Infants and Children
368
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
368